Novacea, Schering-Plough Ink Deal To Develop, Commercialize Cancer Drug Asentar
This article was originally published in The Pink Sheet Daily
Executive Summary
Novacea emphasizes collaborative nature of the agreement, pointing to pre-commercial milestones and larger-than-usual royalties on sales.
You may also be interested in...
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
The firm’s large number of Phase III products are an expensive opportunity.
Schering-Plough’s R&D Spending Surges Ahead Of Sales Gains
The firm’s large number of Phase III products are an expensive opportunity.
Novacea Gains Worldwide Rights To Phase I Cancer Compound From KuDOS
Firm announces agreement with AstraZeneca subsidiary to develop and commercialize banoxantrone, for which it already had North American rights.